ISRCTN52169198已完成未知
A randomised, double-blind placebo-controlled study in patients with reflux symptoms to assess suppression of gastro-oesophageal reflux by 'Gaviscon Double Action peppermint liquid' using the BRAVO System
Reckitt Benckiser Healthcare (UK)0 个研究点目标入组 40 人开始时间: 2010年8月19日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Aged greater than or equal to 18 years and less than or equal to 70 years
- •2. Male and female patients
- •3. Primary diagnosis is those with self-rated at least moderate heartburn or acid regurgitation within 60 minutes following ingestion of a refluxogenic meal on at least three occasions a week at the screening visit
- •4. Agreement to withhold acid suppressant PPI and H2 receptor blocking medications and other medications that affect gastro-intestinal function for 6 days and 3 days respectively prior to the test and during 4 days of monitoring
- •5. Agreement to withhold antacids or alginate preparations, except those administered as part of study procedures for 1 day prior to the test and during 4 days of monitoring
- •6. Patients who gave written informed consent
排除标准
- •1. Those with prominent gastrointestinal symptoms or disease other than reflux (including atypical symptoms, e.g. cough, sore throat, belching, nausea)
- •2. Those with difficulty swallowing (dysphagia), gastrointestinal bleeding, weight loss (greater than 5% body weight) or other alarm symptoms suggestive of neoplastic or severe inflammatory disease within the last 12 months
- •3. Those with a history or symptoms suggestive of Zollinger-Ellison syndrome, gastric carcinoma, previous or current peptic ulcer disease, pernicious anaemia, Barrett's oesophagus or systemic sclerosis
- •4. Those with a history of upper GI surgery or endoscopic interventions such as oesophageal dilatations or mucosal resection
- •5. Those with known hypophosphataemia or phenylketonuria
- •6. Those with severe constipation or history of colonic stenosis
- •7. Those with major oesophageal dysmotility on manometry, e.g. achalasia
- •8. Those with severe reflux oesophagitis on endoscopy (LA grade III - IV) or Barrett's oesophagus on endoscopy
- •9. Those with significant co-morbidity requiring ongoing treatment or investigation
- •10. Those with haematological disorders, bleeding tendency, recurrent nose bleeds or treatment with anti-coagulants
- •11. Those with physical, neurological or psychiatric conditions preventing repeated visits to hospital or compliance with study procedures (e.g. physical impairment/reduced mobility)
- •12. Woman of childbearing potential, who are pregnant or lactating, seeking pregnancy or failing to take adequate contraceptive precautions, (i.e. sexual an oral or injectable contraceptive, an approved hormonal implant or topical patch, an intrauterine device, abstinence [should the subject become sexually active, she must agree to use a double barrier method]). A woman of childbearing potential is defined as any female who has not undergone the menopause or has not had an hysterectomy or surgical sterilisation procedure, e.g. bilateral tubal ligation, bilateral ovariectomy (oophorectomy).
- •13. Those that do not withhold acid-suppressant PPI and H2 receptor blocking medications for 6 days and 3 days respectively prior to the test and during 4 days of monitoring
- •14. Those that do not withhold antacid or alginate medications for 1 days prior to the test and during 4 days of monitoring (5 days in total)
- •15. Those who have any previous history of allergy or known intolerance to any of the study drugs or the following formulation constituents: Gaviscon® liquid: sodium alginate, sodium bicarbonate, calcium carbonate, carbomer, methyl parahydroxybenzoate, propyl parahydroxybenzoate, saccharin sodium, peppermint flavour, sodium hydroxide, Placebo: hydrogenated glucose syrup, peppermint flavour, potassium sorbate, methyl paraben, xanthan gum r80, propyl paraben, citric acid
- •16. Failure to accept or to comply with standard requirements for activity and diet during pH testing
- •17. Those unable in the opinion of the Investigator to comply fully with the study requirements
研究者
相似试验
进行中（未招募）
不适用
A study to assess the safety and effectiveness of the antipsychotic medication risperidone in the treatment of children and adolescents with the psychiatric diagnosis conduct disorder - which is characterised by persistent aggressive and antisocial behaviour - by comparing it to treatment with a non-active substance. Patients will be randomly allocated to treatment with the active- or the non-active substance.Conduct Disorder (DSM-IV-TR312.8xAmerican Psychiatric Association)MedDRA version: 16.0Level: PTClassification code 10064478Term: Conduct disorderSystem Organ Class: 10037175 - Psychiatric disordersEUCTR2011-000567-26-DERadboud University Medical Centre Nijmegen264
进行中（未招募）
不适用
Evaluation of the effect of choline-stabilized orthosilicic acid (ch-OSA®) in patients with tennis elbowateral epicondylitisMusculoskeletal DiseasesLateral epicondylitisISRCTN12631735Bio Minerals NV148
进行中（未招募）
Unknown
Efficacy of herbal supplements (CL22209 and CL22205) on polycystic ovary syndrome (PCOS)CTRI/2023/11/059457CLS Pvt Ltd
招募中
3 期
The effect of using Growth Hormone in Invitro Fertilisation on livebirth ratesinfertilityACTRN12609001060235Robinson Institute389
进行中（未招募）
不适用
A randomised, double blind placebo controlled study in patients with reflux symptoms to assess suppression of gastro-oesophageal reflux by ‘Gaviscon Double Action Peppermint liquid’ using the BRAVO system - Gaviscon Double Action vs placebo studyEUCTR2010-021630-63-GBReckitt Benckiser40